NCT06313567View on ClinicalTrials.gov

Metronomic Capecitabine in Stage III Gastric Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

722

Participants

Timeline

Start Date

March 10, 2024

Primary Completion Date

March 10, 2029

Study Completion Date

March 10, 2029

Conditions
Gastric Cancer
Interventions
DRUG

Metronomic capecitabine group

500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group

OTHER

Observation

observation

Trial Locations (1)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER